Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 7/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.36 |
| ▸ | CDC25B | P30305 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19441639 | 1.00 | SELP (0.44) | SELPTACR1ENPP2PTPN1CDC25B | |
| SCHEMBL19441658 | 0.89 | SELP (0.44) | SELPTACR1PTPN1CDC25B | |
| SCHEMBL20870551 | 0.89 | SELP (0.44) | SELPTACR1PTPN1CDC25B | |
| SCHEMBL20870247 | 0.85 | SELP (0.40) | SELP | |
| SCHEMBL19441640 | 0.85 | SELP (0.40) | SELP | |
| SCHEMBL20019622 | 0.83 | SELP (0.47) | SELPPTPN1CDC25BALDH1A1KMT2A | |
| SCHEMBL19441634 | 0.83 | SELP (0.39) | SELPENPP2KMT2A | |
| SCHEMBL16561945 | 0.83 | SELP (0.39) | SELPENPP2KMT2A | |
| SCHEMBL20870255 | 0.82 | SELP (0.39) | SELPTACR1MCHR1LTA4HEPHX2 | |
| SCHEMBL19441638 | 0.82 | SELP (0.39) | SELPTACR1MCHR1LTA4HEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190099486-A1 | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS | ACADEMIA SINICA (TW) | 2019-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190099486-A1 | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS | UGCG, GALK1, B3GAT3 | SELP 722/4885TACR1 3482/4885ENPP2 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.